A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma

Background: Approximately 50% of melanomas harbor BRAF mutations. Treatment with BRAF +/− MEK inhibition is associated with favorable changes in the tumor microenvironment thus providing the rationale for combining targeted agents with immunotherapy. Methods: Patients with unresectable Stage III or...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncoimmunology
Auteurs principaux: Mooradian, Meghan J., Reuben, Alexandre, Prieto, Peter A., Hazar-Rethinam, Mehlika, Frederick, Dennie T., Nadres, Brandon, Piris, Adriano, Juneja, Vikram, Cooper, Zachary A., Sharpe, Arlene H., Corcoran, Ryan B., Flaherty, Keith T., Lawrence, Donald P., Wargo, Jennifer A., Sullivan, Ryan J.
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2018
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5927481/
https://ncbi.nlm.nih.gov/pubmed/29721378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1423172
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires